12/4
02:57 pm
mrk
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Scotiabank from $105.00 to $120.00. They now have a "sector outperform" rating on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Scotiabank from $105.00 to $120.00. They now have a "sector outperform" rating on the stock.
12/4
02:02 pm
mrk
Merck & Co., Inc. (MRK): A Bull Case Theory [Yahoo! Finance]
Low
Report
Merck & Co., Inc. (MRK): A Bull Case Theory [Yahoo! Finance]
12/4
12:05 pm
mrk
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
Low
Report
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
12/3
04:32 pm
mrk
Merck & Co., Inc. (NYSE:MRK) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
12/2
01:20 pm
mrk
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $92.00 to $120.00. They now have a "buy" rating on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $92.00 to $120.00. They now have a "buy" rating on the stock.
12/1
08:36 am
mrk
Eli Lilly cuts Zepbound price to widen access for obesity drug [BNN Bloomberg (Canada)]
Low
Report
Eli Lilly cuts Zepbound price to widen access for obesity drug [BNN Bloomberg (Canada)]
12/1
06:45 am
mrk
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
Low
Report
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025
11/28
10:04 am
mrk
Merck: Excellence Across The Board [Seeking Alpha]
Low
Report
Merck: Excellence Across The Board [Seeking Alpha]
11/27
02:50 pm
mrk
Merck & Co., Inc. (NYSE:MRK) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Merck & Co., Inc. (NYSE:MRK) had its "hold (c)" rating reaffirmed by analysts at
Weiss Ratings.
11/27
10:44 am
mrk
Follicular Lymphoma Market Trends, Opportunities, Growth Challenges and Competitive Intelligence 2025-2035 [Yahoo! Finance]
Low
Report
Follicular Lymphoma Market Trends, Opportunities, Growth Challenges and Competitive Intelligence 2025-2035 [Yahoo! Finance]
11/26
01:06 pm
mrk
Merck & Co. Stock: Is MRK Outperforming the Healthcare Sector? [Yahoo! Finance]
Low
Report
Merck & Co. Stock: Is MRK Outperforming the Healthcare Sector? [Yahoo! Finance]
11/26
08:32 am
mrk
Why Is Merck Stock Surging? [Forbes]
Low
Report
Why Is Merck Stock Surging? [Forbes]
11/26
07:15 am
mrk
Merck to Participate in the Citi 2025 Global Healthcare Conference
Low
Report
Merck to Participate in the Citi 2025 Global Healthcare Conference
11/26
06:45 am
mrk
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
Low
Report
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference
11/24
08:14 am
mrk
Merck & Co., Inc. (NYSE:MRK) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $125.00 price target on the stock.
Low
Report
Merck & Co., Inc. (NYSE:MRK) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $125.00 price target on the stock.
11/24
06:45 am
mrk
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
Low
Report
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches
11/21
07:30 pm
mrk
Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
Low
Report
Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer
11/21
04:12 pm
mrk
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Low
Report
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
11/21
12:44 pm
mrk
Merck Keytruda formulations approved in U.S. for bladder cancer [Seeking Alpha]
Low
Report
Merck Keytruda formulations approved in U.S. for bladder cancer [Seeking Alpha]
11/21
12:27 pm
mrk
Lilly becomes first drugmaker to hit US$1 trillion valuation on weight-loss demand [BNN Bloomberg (Canada)]
Low
Report
Lilly becomes first drugmaker to hit US$1 trillion valuation on weight-loss demand [BNN Bloomberg (Canada)]
11/20
12:01 am
mrk
133-year-old big pharma company plans layoffs, files WARN notice [Yahoo! Finance]
Low
Report
133-year-old big pharma company plans layoffs, files WARN notice [Yahoo! Finance]
11/19
07:37 am
mrk
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection [Yahoo! Finance]
Low
Report
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection [Yahoo! Finance]
11/19
06:45 am
mrk
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
Low
Report
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection
11/19
06:44 am
mrk
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union [Yahoo! Finance]
Low
Report
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union [Yahoo! Finance]
11/19
06:30 am
mrk
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union
Low
Report
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union